News Releases

July 17, 2019
Unum Therapeutics to Present at the Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass. , July 17, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced that Charles Wilson , Ph.D.,
July 2, 2019
Unum Therapeutics Announces Regulatory Update from Phase 1 Trial with ACTR087
CAMBRIDGE, Mass. , July 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced that the U.S.
June 13, 2019
Unum Therapeutics Strengthens and Expands Leadership Team
– Matthew Osborne Appointed as Chief Financial Officer – – Jessica Sachs Promoted to Chief Medical Officer – – Mert Aktar Appointed as Head of Business and Corporate Development – CAMBRIDGE, Mass. , June 13, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc.
May 13, 2019
Unum Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
- Advancing ACTR Clinical Programs in Non-Hodgkin Lymphoma, Multiple Myeloma, and HER2+ Advanced Cancers Through Dose Escalation Studies with Data Expected from All Four Ongoing Trials in Second Half of 2019 - - Advancing and Expanding BOXR Pipeline Focused on Solid Tumor Cancers Through
May 6, 2019
Unum Therapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 13, 2019 at 8:00 A.M. ET
CAMBRIDGE, Mass. , May 06, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer using its novel T cell technology platforms, today announced that the company will host a
April 2, 2019
Unum Therapeutics to Present at Two Upcoming Investor Conferences
CAMBRIDGE, Mass. , April 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced that Charles Wilson , Chief
March 28, 2019
Unum Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
- Advancing ATTCK-20-03 Phase 1 Trial in CD20+ Non-Hodgkin Lymphoma Toward Expansion Phase; Completing ATTCK-20-2 Study - - Continued Dose Escalation of ATTCK-17-01 Trial in Multiple Myeloma - - First Solid Tumor Trial, ATTCK-34-01, Initiated in HER2+ Advanced Cancers – - Expanding Solid Tumor
March 21, 2019
Unum Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on March 28, 2019 at 8:00 A.M. ET
CAMBRIDGE, Mass. , March 21, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer using its novel T cell technology platforms, today announced that the company will host a
March 5, 2019
Unum Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference 2019
CAMBRIDGE, Mass. , March 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced that Charles Wilson , Chief
January 4, 2019
CORRECTING and REPLACING -- Unum Therapeutics Announces 2019 Goals and Expected Milestones
In a release issued yesterday under the same headline by  Unum Therapeutics Inc.  (NASDAQ: UMRX), please note the anticipated 2019 milestone for BOXR1030 has been changed from initiating clinical development to initiating preclinical development in the last paragraph.
Displaying 1 - 10 of 12
The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.